Orphan medicines: the high cost of hope

Orphan drugs can transform the lives of patients with rare diseases, but they often come at an extremely high cost. Sarah Houlton discusses the incentives that are encouraging pharma investment in orphan drug research and the steps that NICE and the NHS are taking to budget for these treatments as they come to market.
Source: Prescriber - Category: Primary Care Authors: Tags: Analysis Source Type: research